CLINICAL TRIALS PROFILE FOR PENICILLIN V

505(b)(2) Clinical Trials for Penicillin V

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Indication	NCT05069974 ↗	Alternative Antibiotics for Syphilis	Recruiting	Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia	Phase 3	2021-10-01	The Trep-AB clinical trial will test the efficacy of an investigational neuropenetrative drug, Linezolid (LZD), compared to standard treatment, Benzathine penicillin G (BPG), for early syphilis in humans. The overarching idea of the work proposed herein is to investigate the use of LZD to treat syphilis, conducting a randomized controlled clinical trial to evaluate this new indication of a known antibacterial agent. It is estimated to include 360 participants.

All Clinical Trials for Penicillin V

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000585 ↗	Penicillin Prophylaxis in Sickle Cell Disease (PROPS)	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	1983-08-01	To determine whether the regular daily administration of oral penicillin would reduce the incidence of documented infection due to Streptococcus pneumoniae in children with sickle cell anemia.
NCT00000648 ↗	A Pilot Study Evaluating Penicillin G and Ceftriaxone as Therapies for Presumed Neurosyphilis in HIV Seropositive Individuals	Completed	Hoffmann-La Roche	N/A	1969-12-31	To provide information on the response of HIV infected, neurosyphilis patients to the currently recommended treatment for neurosyphilis; to determine whether possible co-infection with both HIV and syphilis makes more difficult the diagnosis of syphilis; to explore the usefulness of an alternative treatment which, if effective, would permit outpatient treatment for neurosyphilis that until now required prolonged hospitalization. Studies suggest that syphilis treatment failures may be more common in HIV infected patients than in patients without HIV infection and that treatment failures occur due to and/or are displayed as central nervous system (CNS) involvement. Very little is known about the best treatment course for neurosyphilis in patients who are also infected with HIV.
NCT00000648 ↗	A Pilot Study Evaluating Penicillin G and Ceftriaxone as Therapies for Presumed Neurosyphilis in HIV Seropositive Individuals	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	N/A	1969-12-31	To provide information on the response of HIV infected, neurosyphilis patients to the currently recommended treatment for neurosyphilis; to determine whether possible co-infection with both HIV and syphilis makes more difficult the diagnosis of syphilis; to explore the usefulness of an alternative treatment which, if effective, would permit outpatient treatment for neurosyphilis that until now required prolonged hospitalization. Studies suggest that syphilis treatment failures may be more common in HIV infected patients than in patients without HIV infection and that treatment failures occur due to and/or are displayed as central nervous system (CNS) involvement. Very little is known about the best treatment course for neurosyphilis in patients who are also infected with HIV.
NCT00001359 ↗	Preventive Measures for Childhood-Onset Obsessive-Compulsive Disorder and Tic Disorders (PANDAS Subgroup)	Completed	National Institute of Mental Health (NIMH)	Phase 2	1993-04-01	A subgroup of patients with childhood-onset obsessive-compulsive disorder (OCD) and/or tic disorders has been identified who share a common clinical course characterized by dramatic onset and symptom exacerbations following group A beta-hemolytic streptococcal (GABHS) infections. This subgroup is designated by the acronym PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal infections). There are five clinical characteristics that define the PANDAS subgroup: presence of OCD and/or tic disorder; prepubertal symptom onset; sudden onset or abrupt exacerbations (relapsing-remitting course); association with neurological abnormalities (presence of adventitious movements or motoric hyperactivity during exacerbations); and temporal association between symptom exacerbations and GABHS infections. In this subgroup, periodic exacerbations appear to be triggered by GABHS infections in a manner similar to that of Sydenham's chorea, the neurological variant of rheumatic fever. Rheumatic fever is a disorder with a presumed post-streptococcal autoimmune etiology. The streptococcal pathogenesis of rheumatic fever is supported by studies that have demonstrated the effectiveness of penicillin prophylaxis in preventing recurrences of this illness. A trial of penicillin prophylaxis in the PANDAS subgroup demonstrated that penicillin was not superior to placebo as prophylaxis against GABHS infections in these children, but this outcome was felt to be secondary to non-compliance with treatment, and there was no decrease in the number of neuropsychiatric symptom exacerbations in this group. In a study comparing azithromycin and penicillin, both drugs were completely effective in preventing streptococcal infections - there were no documented titer elevations during the year-long study period for children taking either penicillin or azithromycin. Comparable reductions in the severity of tics and obsessive-compulsive symptoms were also observed. Thus, penicillin was not performing as an "active placebo" as originally postulated, but rather provided effective prophylaxis against Group A beta-hemolytic streptococcal. Both azithromycin and penicillin appear to be effective in eliminating GABHS infections, and reducing neuropsychiatric symptom severity; thus, between-group differences are negligible. Since increasing the "n" to demonstrate superiority of one prophylactic agent over another would be impractical, we have amended the study design to address two issues: 1. To determine if antibiotics prophylaxis against GABHS infections is superior to placebo in prolonging periods of remission among children in the PANDAS subgroup. 2. To determine if antibiotics prophylaxis against GABHS infections is superior to placebo in improving overall symptom severity for obsessive-compulsive symptoms and tics among children in the PANDAS subgroup. Because penicillin has a narrower therapeutic index and is less expensive than azithromycin, it is the preferable prophylactic agent. Further, penicillin (250 mg orally twice a day) has a long history of providing safe and effective prophylaxis for rheumatic fever and is the first line oral therapy recommended by the American Heart Association. Thus, penicillin has been chosen as the prophylactic antibiotic in the present study. Blister packs are used to increase compliance and to allow for easier documentation of missed doses.
NCT00002682 ↗	Antibiotic Therapy and Antacids in Patients With Malt Lymphoma of the Stomach	Completed	National Cancer Institute (NCI)	Phase 2	1995-08-10	RATIONALE: Antibiotic therapy and antacids are used to treat Helicobacter pylori infection of the stomach. These treatments may also have an effect on gastric MALT lymphoma of the stomach. PURPOSE: Phase II trial to study the effectiveness of antibiotic therapy with amoxicillin, clarithromycin, tetracycline, and metronidazole plus antacids in patients with MALT lymphoma of the stomach.

Clinical Trial Conditions for Penicillin V

Condition Name

Condition Name for Penicillin V
Intervention	Trials
Syphilis	12
Penicillin Allergy	11
Helicobacter Pylori Infection	10
Sepsis	7

Condition MeSH

Condition MeSH for Penicillin V
Intervention	Trials
Infections	33
Infection	25
Communicable Diseases	24
Syphilis	17

Clinical Trial Locations for Penicillin V

Trials by Country

Trials by Country for Penicillin V
Location	Trials
United States	206
China	25
Canada	21
Australia	18
Israel	11

Trials by US State

Trials by US State for Penicillin V
Location	Trials
California	15
Ohio	12
New York	12
Texas	11
North Carolina	9

Clinical Trial Progress for Penicillin V

Clinical Trial Phase

Clinical Trial Phase for Penicillin V
Clinical Trial Phase	Trials
PHASE4	11
PHASE3	6
PHASE2	5

Clinical Trial Status

Clinical Trial Status for Penicillin V
Clinical Trial Phase	Trials
Completed	89
RECRUITING	37
Not yet recruiting	27

Clinical Trial Sponsors for Penicillin V

Sponsor Name

Sponsor Name for Penicillin V
Sponsor	Trials
World Health Organization	7
National Institute of Allergy and Infectious Diseases (NIAID)	6
University of Oxford	5

Sponsor Type

Sponsor Type for Penicillin V
Sponsor	Trials
Other	379
Industry	26
NIH	11

Last updated: April 24, 2026

Penicillin V: Clinical Trial Status Update and Market Outlook

What is the current clinical-trial status of penicillin V?

Penicillin V (phenoxymethylpenicillin) is an established, off-patent antibiotic with no current, mainstream clinical development profile that would show ongoing pivotal or late-stage trials in major registries. Clinical activity is concentrated in historical use and in smaller, non-centralized evaluations rather than new global phase programs.

Practical read-through for R&D and investment

• No meaningful near-term “pipeline event” cadence is attributable to penicillin V from major registries because the compound is not positioned as a registrational development asset in the way modern therapeutics are.
• Any clinical trial activity is more likely to be formulation, dosing optimization, microbiology surveillance, or comparator studies conducted on a limited scale rather than global phase registration programs.

Evidence base (registry search reality) Penicillin V is not widely listed as an active investigational drug in major modern trial pipelines, and no current phase-spanning program is evident from public registry listings. The compound’s clinical evidence base is dominated by older trials and standard-of-care references rather than ongoing phase work.

How does penicillin V compete in the antibiotics market?

Penicillin V sits in a crowded, mature segment of antibacterials where competition is driven by:

• Generic penetration
• Narrow-to-moderate spectrum use
• Stewardship pressure and physician prescribing patterns
• Distribution strength in primary care and pediatrics

Segment positioning

• Core use profile: oral treatment options for selected streptococcal and other susceptible bacterial infections where phenoxymethylpenicillin is appropriate.
• Competitive set: amoxicillin and other oral penicillins, first-generation cephalosporins, and macrolides as alternatives in real-world prescribing when tolerance or resistance patterns shift.
• Key constraint: beta-lactam resistance and physician preference trends favor broader or more convenient regimens in many settings.

Market structure

• This market is largely generic and volume-driven, with low pricing power and a high need for supply reliability, regulatory compliance, and cost competitiveness.
• Penicillin V’s market performance depends primarily on regional formulary placement and local guideline alignment rather than patent-driven product differentiation.

What is the current market size and where does demand come from?

A precise, drug-specific global market size for penicillin V alone is not consistently published in mainstream commercial forecasting databases in a way that supports a single authoritative number across geographies. In practice, penicillin V is typically captured under:

• “Oral penicillins” and “penicillins” categories
• Country-level antibiotic reimbursement and formulary reporting
• Generic antibacterial procurement channels

Demand drivers that affect penicillin V

• Streptococcal infection incidence (including pharyngitis and related syndromes)
• Pediatric and primary-care prescribing patterns
• Guideline alignment for oral penicillin therapy where penicillin V remains recommended
• Resistance landscape among streptococci and common community pathogens
• Formulary and reimbursement changes that can rapidly shift shares to amoxicillin or other generics

What market projections are credible for penicillin V (directional outlook)?

Given the maturity and generic status, credible projections are directional and tied to class-level trends rather than a bespoke growth thesis.

Base-case directional projection (typical for mature generic antibiotics)

• Volume: stable to modestly down in regions where stewardship reduces unnecessary antibiotic use, balanced by persistent incidence-driven prescribing.
• Pricing: flat to downward in most markets due to generic competition and procurement tenders.
• Share: can swing modestly based on guideline updates, local clinician preference, and supply chain constraints among competing oral penicillins.

Key sensitivities

1. Guideline changes that alter first-line preference between penicillin V and amoxicillin.
2. Regional procurement and tender outcomes that determine which generic brands win volume.
3. Resistance and safety dynamics that change how often clinicians choose penicillins versus alternatives.
4. Supply continuity since antibiotic shortages can temporarily reallocate share.

Where are the main “clinical” value levers for penicillin V now?

Since penicillin V is not typically pursued as a novel registrational candidate, current value levers are product and evidence-adjacent:

1) Formulation and bioavailability work

• Improved oral formulation stability, palatability for pediatric use, and dosing convenience.
• Bioequivalence studies and incremental quality enhancements, which can matter in tender settings even without new efficacy claims.

2) Narrow-spectrum stewardship positioning

• Evidence-backed use aligned with organism susceptibility.
• Real-world microbiology support for narrow-spectrum antibiotics where appropriate.

3) Safety management and substitution pathways

• Clear handling of allergy histories, cross-reactivity guidance, and substitution to non-penicillin options when needed.

What does the evidence base say about penicillin V use and safety?

Penicillin V’s clinical role remains anchored in decades of bacteriology and clinical experience with penicillin-class antibiotics.

Mechanism and clinical expectation

• It is a beta-lactam antibiotic (phenoxymethylpenicillin) used against susceptible organisms.
• Clinical efficacy depends on pathogen susceptibility and appropriate diagnosis.

Safety profile

• Beta-lactam class adverse events include hypersensitivity reactions, gastrointestinal effects, and other class-associated risks.
• Standard prescribing requires allergy screening and appropriate duration selection.

Regulatory and labeling

• Penicillin V is widely regulated as a generic antibiotic in many jurisdictions, with labeling focused on indications, dosing, contraindications, and warnings consistent with beta-lactam safety frameworks.

How do approvals and patents affect penicillin V economics?

Penicillin V is off-patent, so:

• Brand economics are driven by marketing and channel access, not exclusivity.
• Competitive intensity is structurally high.
• Cash flows track generic cycle dynamics and procurement behavior.

Implication for forecasts

• Sustainable growth requires operational advantages: supply, cost, dossier quality, regulatory maintenance, and ability to win tenders.
• No exclusivity-based upside is typical for penicillin V.

What investors and R&D teams should watch next

Even without a novel clinical pipeline, penicillin V outcomes can change through secondary mechanisms:

Forecast-critical KPIs

• Country-level tender volumes for oral penicillins
• Share shifts between penicillin V and amoxicillin based on formulary inclusion
• Pediatric prescribing shares
• Evidence updates in stewardship guidance that reinforce or reduce oral penicillin use

Near-term event types

• Generic launches and supply disruptions
• Formulary revisions tied to guideline updates
• Lab susceptibility shifts that affect clinician comfort with narrow-spectrum penicillin therapy

---

Key Takeaways

• Penicillin V is a mature, off-patent antibiotic with no prominent, ongoing global phase clinical development footprint.
• Market outcomes are primarily driven by generic competition, procurement, formulary placement, and stewardship-guided prescribing rather than registrational innovation.
• Directional outlook is stable-to-modestly declining volume in many markets with pricing pressure, unless specific tender or guideline shifts reallocate share.

FAQs

1) Is penicillin V still actively studied in phase 2 or phase 3 trials?

Publicly visible, global phase programs are not characteristic of penicillin V’s modern development profile; activity is more consistent with limited, formulation or comparative studies than late-stage registrational trials.

2) What determines penicillin V demand in practice?

Demand tracks incidence of susceptible infections and clinician prescribing patterns, which are shaped by guidelines, formulary access, resistance patterns, and patient mix (notably pediatrics and primary care).

3) Why does penicillin V face tougher competition than branded antibiotics?

Generic substitution is easy across oral penicillin options, so pricing is pressured and share depends on tender outcomes and channel access rather than exclusivity.

4) What is the most important market sensitivity for penicillin V?

Guideline and formulary shifts that change the preferred oral penicillin choice between penicillin V and alternatives, especially amoxicillin.

5) What is the most realistic path to economic differentiation?

Operational and regulatory execution: low cost of goods, consistent supply, strong dossier quality, and winning procurement tenders via reliability and documentation.

---

References

[1] National Center for Biotechnology Information. “Penicillin V.” PubChem Compound Summary. https://pubchem.ncbi.nlm.nih.gov/
[2] European Medicines Agency (EMA). Public medicine information on penicillin-class antibiotics and related assessments (beta-lactam labeling conventions). https://www.ema.europa.eu/
[3] U.S. National Library of Medicine. ClinicalTrials.gov: Penicillin V search results and study listings. https://clinicaltrials.gov/